WO2018119519A1 - Ghr-106 chimeric antigen receptor construct and methods of making and using same - Google Patents
Ghr-106 chimeric antigen receptor construct and methods of making and using same Download PDFInfo
- Publication number
- WO2018119519A1 WO2018119519A1 PCT/CA2017/051601 CA2017051601W WO2018119519A1 WO 2018119519 A1 WO2018119519 A1 WO 2018119519A1 CA 2017051601 W CA2017051601 W CA 2017051601W WO 2018119519 A1 WO2018119519 A1 WO 2018119519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ghr
- car
- domain
- cells
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract description 142
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 230000027455 binding Effects 0.000 claims abstract description 62
- 201000011510 cancer Diseases 0.000 claims abstract description 57
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 101000996727 Homo sapiens Gonadotropin-releasing hormone receptor Proteins 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims description 105
- 210000004027 cell Anatomy 0.000 claims description 99
- 239000002773 nucleotide Substances 0.000 claims description 88
- 125000003729 nucleotide group Chemical group 0.000 claims description 88
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 86
- 210000002865 immune cell Anatomy 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 22
- 108090000695 Cytokines Proteins 0.000 claims description 22
- 239000013612 plasmid Substances 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 230000000139 costimulatory effect Effects 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 11
- 230000003834 intracellular effect Effects 0.000 claims description 11
- 230000011664 signaling Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 9
- 102000000704 Interleukin-7 Human genes 0.000 claims description 9
- 108010002586 Interleukin-7 Proteins 0.000 claims description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 230000002147 killing effect Effects 0.000 claims description 9
- 230000001124 posttranscriptional effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 230000005754 cellular signaling Effects 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 241000714474 Rous sarcoma virus Species 0.000 claims description 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108091027981 Response element Proteins 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102100021696 Syncytin-1 Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940100994 interleukin-7 Drugs 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 18
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 102100027211 Albumin Human genes 0.000 description 12
- 108010088751 Albumins Proteins 0.000 description 12
- 108010021290 LHRH Receptors Proteins 0.000 description 12
- 102000008238 LHRH Receptors Human genes 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 11
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 10
- 241000713666 Lentivirus Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 10
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229950007870 hexadimethrine bromide Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 101150110792 GNRHR gene Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101100444397 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ECM32 gene Proteins 0.000 description 1
- 101100177365 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEL1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Some embodiments of the present invention relate to the fields of immunology, cell biology, molecular biology, and medicine, including cancer medicine. Some embodiments of the present invention relate to the field of a chimeric antigen receptor (CAR) that targets gonadotropin-releasing hormone (GnRH) receptor, nucleotide constructs encoding such a CAR, and methods of making and using same.
- CAR chimeric antigen receptor
- GnRH gonadotropin-releasing hormone
- GnRH Gonadotropin releasing hormone receptors are located on the external membrane of selected cell types. Through specific binding to the GnRH receptor, the anterior pituitary releases GnRH, a decapeptide hormone that stimulates the release of gonadotropin, luteinizing hormone (LH) and follicle stimulating hormone (FSH).
- LH luteinizing hormone
- FSH follicle stimulating hormone
- GnRH or its analogs can have anti-proliferative effects on cancer cells (Pati, D., et al., Endocrin (1995) 136:75-84; Choi, K.C., et al., J Clin Endocrinol & Metab (2001) 86:5075-5078, both of which are incorporated by reference herein for all purposes).
- GnRH analogs have been used to treat different cancers in humans and disorders in fertility regulation (Gnananpragasam, V.J., et al., J Pathol (2005) 206: 205-213; So, W. K., et al., FEBS Journal (2008) 275: 5496-551 1).
- GnRH and GnRH analogs have a relatively short half-life in circulation.
- monoclonal antibodies generally have a relatively long half-life in circulation.
- the GHR-106 monoclonal antibody was generated in mice immunized against synthetic peptides corresponding to the extracellular domains of the human GnRH receptor. GHR-106 was found to behave as a GnRH analog. GHR-106 has a much longer half-life than other GnRH analogs known in the art. GnRH analogs have been known for decades to treat different cancers in humans as well as disorders in fertility regulation.
- murine GHR-106 and humanized GHR-106 antibodies behave similarly to GnRH peptide analogs in that they can induce in vitro apoptosis in treated cancer cells. Furthermore, unlike GnRH peptide analogs, both the murine and
- humanized forms of GHR-106 can induce complement-dependent cytotoxicity in treated cancer cells.
- CARs Chimeric antigen receptors
- CAR-T T cell therapy
- CAR-T T cell therapy
- the modified T cells express CARs, which are antigen receptors recognizing cell surface antigens on tumor cells.
- the modified T cells can initiate an immune response, such as the release of cytokine to induce tumor cell death.
- Attempts in using CAR-T to treat cancer have met with some success.
- Successful examples have been reported for CAR- T cell therapy of different types of blood cancers, for example by using a CD19-related CAR platform.
- One aspect of the invention provides a nucleotide vector capable of expressing a GHR-106 CAR.
- the GHR-106 CAR encodes a polypeptide having from N-terminal to C- terminal an antigen binding domain capable of binding to an extracellular domain of human GnRH receptor, a hinge domain, a transmembrane domain; and an intracellular T cell signaling domain.
- the antigen binding domain is an scFv of GHR-106.
- One aspect of the invention provides a polypeptide that is a GHR-106 CAR that has an antigen binding domain capable of binding to the extracellular domains of human GnRH receptor.
- the polypeptide that is a GHR-106 CAR has an antigen binding domain capable of binding to an extracellular domain of human GnRH receptor, a transmembrane domain, and an intracellular T cell signaling domain.
- immune cells that express the GHR-106 CAR are able to selective bind to and kill cells expressing the human GnRH receptor.
- the cells expressing the human GnRH receptor are cancer cells.
- One aspect of the invention provides a method of producing an immune cell capable of expressing a GHR-106 CAR.
- the method involves isolating the immune cells from the subject and genetically engineering the immune cells to express a GHR-106 CAR.
- the genetic engineering can be carried out using a lentiviral vector.
- the immune cells are introduced into the body of a patient suffering from cancer or another disorder involving a high surface expression of human GnRH receptor to treat the cancer or the disorder.
- FIGS. 1A andl B show amino acid and nucleotide sequences, respectively, of the heavy chain of a humanized GHR-106 antibody (SEQ ID NOS:1-2).
- FIGS. 1 C-1 D show the amino acid and nucleotide sequences, respectively, of the light chain of a humanized GHR-106 antibody (SEQ ID NOS:3-4).
- the sequences of the humanized GHR-106 antibody were deduced from antibodies produced by a stable cell line, UY464-GHR106.
- FIG. 2A is a schematic diagram showing the domains of a first example embodiment of a nucleotide vector capable of expressing a GHR-106 CAR.
- the illustrated embodiment is a CAR lentiviral vector.
- FIGS. 2B and 2C show amino acid sequences of the scFv fragment of the exemplary GHR-106 CAR nucleotide vector construct shown in FIG. 2A.
- FIG. 2B shows the amino acid sequence of the V H domain of the scFv fragment (SEQ ID NO:5).
- FIG. 2C shows the amino acid sequence of the V L domain of the scFv fragment (SEQ ID NO:6).
- FIG. 2D shows the protein sequence of the exemplary GHR-106 CAR construct shown in FIG. 2A fused with an IL7 cytokine (SEQ ID NO:7). Although the sequences of FIG. 2D have been separated into different sections to illustrate the different domains of the GHR-106 CAR fusion protein construct, the sequences are one continuous polypeptide.
- FIG. 3 is a schematic diagram showing schematically an example embodiment of a complete recombinant GHR-106 CAR-T lentiviral vector construct.
- the amino acid sequence encoded by the GHR-106 CAR-T nucleotide vector construct comprises SEQ ID NO:7.
- the gene sequence of the GHR-106 CAR nucleotide vector construct is present in the form of a plasmid that can be used as a transfer plasmid to produce lentivirus capable of introducing the nucleotide vector capable of expressing the GHR-106 CAR into an immune cell, e.g. a T cell.
- FIG. 4 shows the molecular weights of DNA fragments produced by digesting the exemplary GHR-106 CAR nucleotide vector construct shown in FIG. 3 with restriction endonucleases EcoRI and Xba ⁇ .
- FIGS. 5A and 5B show qPCR standard curves used to reveal titers by lentivirus titration.
- FIG. 5A shows the WPRE standard curve and
- FIG. 5B shows the ALB standard curve.
- FIGS. 6A and 6B show validation of the insertion of the GHR-106 CAR nucleotide vector into transduced T cells by using a standard curve of Ct (cycle threshold) value to determine copy number.
- FIG. 6A shows the ALB standard curve and
- FIG. 6B shows the LTR standard curve. These two standard curves were used to determine the average number of copies of the exemplary GHR-106 CAR-T nucleotide vector construct in genetically modified T cells.
- FIGS. 7A, 7B and 7C show the results of three repeats of a lysis assay, where genetically modified T cells comprising copies of the exemplary GHR-106 CAR nucleotide vector construct were co-cultured with tumor cells. Data for three repeats of CAR-T validation demonstrated by lysis of target tumor cells by GHR-106 CAR-T cells as measured by lactate dehydrogenase (LDH) assay are shown.
- LDH lactate dehydrogenase
- FIGS. 8A, 8B, 8C, 9A, 9B, 9C and 10A, 10B, 10C show standard curves for three separate repeats of the same experiment for IL-2, IFN-gamma and IL-7, respectively.
- D IL-2
- nucleic acid molecule refers to a polymeric form of nucleotides of any length.
- the nucleotides can include either ribonucleotides (RNA) or deoxyribonucleotides (DNA).
- antibody and “immunoglobulins” refer to antibodies of any isotype and fragments of antibodies that bind specifically to an antigen. Some examples of antibodies include but are not limited to humanized antibodies, chimeric antibodies, and proteins comprising an antigen-binding portion of an antibody.
- antibody fragment refers to a portion of an antibody.
- Some examples of antibody fragments include but are not limited to an antigen binding (Fab) fragment, an F(ab') 2 fragment, an Fab' fragment, or a variable domain (Fv).
- Fab antigen binding
- Fv variable domain
- single-chain variable fragment refers to a single polypeptide chain, comprising the variable regions of the light (VL) and heavy (V H ) chains of an antibody.
- VL variable regions of the light
- V H heavy chains of an antibody.
- the V L and V H regions are joined by a suitable linker.
- affinity refers to the strength of the binding interaction between a single biomolecule and its ligand or binding partner.
- the strength of the binding interaction is measured by the equilibrium constant for the reversible binding of two molecules, which can be expressed as a dissociation constant (Kd).
- Desired clinical results can include, but are not limited to, reduction or alleviation of at least one symptom of a disease.
- treatment can be diminishment of at least one symptom of disease, diminishment of extent of disease, stabilization of disease state, prevention of spread of disease, delay or slowing of disease progression, palliation of disease, diminishment of disease reoccurrence, remission of disease, prolonging survival with disease, or complete eradication of disease.
- cancer cell and “tumor cell” refer to cells, the growth and division of which can be typically characterized as unregulated. Cancer cells can be of any origin, including benign and malignant cancers, metastatic and non-metastatic cancers, and primary and secondary cancers.
- chimeric antigen receptor refers to an engineered receptor.
- a typical CAR has an antigen binding domain that binds to a desired target antigen, a transmembrane domain, and an intracytoplasmic domain.
- the antigen binding domain of a CAR can be provided by the scFv of a monoclonal antibody.
- the transmembrane domain and the intracytoplasmic domain can be provided by the CD3-zeta
- a typical CAR will also include a signal peptide at its amino-terminal end, to direct the nascent translated protein into the endoplasmic reticulum so that the antigen binding domain will be presented on the surface of the immune cell in which the CAR is expressed.
- a chimeric antigen receptor (CAR) comprising an antigen- binding fragment of a humanized GHR-106 monoclonal antibody is provided, and is referred to herein as a GHR-106 CAR.
- a GHR-106 CAR is a CAR that is able to bind to extracellular domains of the human GnRH receptor.
- the GHR-106 CAR comprises the scFv fragment of a humanized GHR-106 antibody, and can be expressed following introduction of a nucleotide vector encoding the GHR-106 CAR into suitable immune cells, for example, T cells.
- the antigen binding domain of the GHR-106 CAR binds to the extracellular domains of human GnRH receptor.
- the GHR- 106 CAR exhibits similar binding affinity and specificity towards the human GnRH receptor as does a humanized GHR-106 antibody.
- Some embodiments of the invention relate to the field of a lentiviral chimeric antigen receptor (CAR) nucleotide construct including portions of a humanized GHR-106 gene that provides a nucleotide vector capable of expressing a GHR-106 CAR in a transduced immune cell.
- Humanized GHR-106 is murine GHR-106 monoclonal antibody in humanized form which recognizes and binds specifically the extracellular domains of the human GnRH receptor.
- the human GnRH receptor is highly expressed on the surface of cancer cells of many tissue origins.
- the GHR-106 CAR-transduced immune cells upon transduction of a nucleotide vector encoding the GHR-106 CAR into suitable immune cells, for example, T cells or NK cells isolated from an individual patient, the GHR-106 CAR-transduced immune cells will then express a GHR-106 CAR construct with an antigen binding region comprising an scFv chain of a humanized GHR-106 antibody.
- This immunoglobulin chain will bind to surface- expressed GnRH receptor on cancer cells and result in cytotoxic killing of the cancer cells.
- the human GnRH receptor is expressed in particular on the surface of cancer cells in hormone-sensitive forms of cancer. Therefore, the GHR-106 CAR system can potentially be utilized for therapeutic applications for treatment of human hormone- sensitive cancers.
- GHR-106-related CAR-T technology in cancer immunotherapy can be achieved by genetically modifying appropriate immune cells, e.g. T cells, by insertion of a nucleotide vector encoding GHR-106 CAR, so that those immune cells will subsequently express a GHR-106 CAR comprising an scFv of GHR-106 that can bind to the GnRH receptor expressed on the cancer cell surface to induce apoptosis and related cytotoxic killing of tumor cells, in vitro and in vivo.
- appropriate immune cells e.g. T cells
- a GHR-106 CAR construct can be transduced into isolated immune cells, e.g. T cells, of a given patient. These modified immune cells, e.g. T cells, from the given patient can be expanded by in vitro culture, and then transfused to the same given patient.
- the isolated immune cells, e.g. T cells are obtained from a healthy subject, genetically modified to insert a nucleotide vector capable of expressing a GHR- 106 CAR therein, and then introduced into the bloodstream of a patient suffering from cancer.
- Cancer immunotherapy using a GHR-106 CAR can be used in the treatment of cancer, for example for inhibition and/or reduction of tumor growth.
- the antigen binding domain of the GHR-106 CAR comprises a peptide that binds to the extracellular domains of the GnRH receptor in a manner similar to the GHR-106 antibody.
- US patent No. 9273138 to Lee discloses the nucleotide sequence of humanized GHR-106 antibody. In that reference, the sequence was verified by repeated sequencing and molecular biological analysis. The antibody-producing stable cell line for a humanized GHR-106 antibody was established and disclosed by that reference.
- FIGS. 1A-1 D The amino acid and nucleotide sequences of an example embodiment of a humanized GHR-106 monoclonal antibody are shown in FIGS. 1A-1 D.
- the heavy chain of the humanized GHR-106 antibody is encoded by the nucleotide sequence shown in FIG. 1 B (SEQ ID NO:2).
- the light chain of the humanized GHR-106 antibody is encoded by the nucleotide sequence shown in FIG. 1 D (SEQ ID NO:4).
- FIGS. 1A and 1 C show the corresponding amino acid sequences of the heavy and light chains, respectively, of the humanized GHR-106 antibody (SEQ ID NOS: 1 and 3, respectively).
- FIG. 1A and 1 C show the corresponding amino acid sequences of the heavy and light chains, respectively, of the humanized GHR-106 antibody (SEQ ID NOS: 1 and 3, respectively).
- FIG. 2B shows the amino acid sequence of the heavy chain (V H ) of the scFv of the humanized GHR-106 antibody (SEQ ID NO:5)
- FIG. 2C shows the amino acid sequence of the light chain (V
- the GHR-106 CAR comprises from N-terminal to C-terminal a signal peptide 110, a V H fragment of a GHR-106 monoclonal antibody 112, a linker 114, a V L fragment of a GHR- 106 monoclonal antibody 116, a hinge region 118, a transmembrane domain 120, a costimulatory domain 122, and a CD3 zeta subunit domain 124.
- the signal peptide 110 is used to direct the translated GHR-106 CAR into the endoplasmic reticulum, so that the antigen binding domain of the GHR-106 CAR will be expressed on the surface of an immune cell.
- the signal peptide 110 comprises the interleukin 2 signaling sequence (IL2ss), which is used to direct the CAR for cell membrane expression in an immune cell.
- IL2ss interleukin 2 signaling sequence
- any signaling domain that directs the CAR to be appropriately expressed in a membrane of an immune cell could be used.
- the antigen binding domain in the exemplary embodiment of FIG. 2A comprises the VH region 112, linker 114 and V L region 116 that together are an scFv of a GHR-106 monoclonal antibody.
- the antigen binding domain of the GHR-106 CAR comprises the scFv of a humanized GHR-106 antibody, having the V H and V L regions of the humanized GHR-106 antibody having SEQ ID NOS:5 and 6, respectively shown in FIGS. 2B and 2C, joined by a peptide linker.
- sequences of the V H and V L regions of antigen binding fragment of the GHR-106 CAR i.e. the scFv of GHR-106
- any suitable peptide linker sequence could be used to join the V H and V L regions of the scFV of the GHR-106 antibody in the GHR-106 CAR.
- Some parameters limiting the nature of a linker used in an scFV are that it be sufficiently soluble and that it allow the V H and V L regions of the antibody to bind to the target antigen.
- the linker used in the scFV of the GHR-106 antibody can be between about 10 and about 25 amino acids in length, including any value therebetween e.g. 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23 or 24 amino acids in length.
- the linker used in the scFV of the GHR-106 antibody is rich in glycine.
- the linker used in the scFV of the GHR-106 antibody includes a plurality of serine and/or threonine residues, to enhance the solubility of the linker.
- the linker region of the scFv joins the C- terminus of the V H portion of the GHR-106 antibody with the N-terminus of the V L portion of the GHR-106 antibody
- the linker region of the scFv could join the C-terminus of the V L portion of the GHR-106 antibody with the N-terminus of the V H portion of the GHR-106 antibody.
- the antigen binding domain of the GHR-106 CAR enables immune cells that have been genetically engineered with a nucleotide vector encoding the GHR-106 CAR to specifically bind to the extracellular domains of human GnRH receptor, which is expressed in cancer cells.
- the GHR-106 CAR binds to an epitope in the N-terminal amino acid positions 1-29 of the human GnRH receptor.
- the antigen binding domain of the GHR-106 CAR has a specificity and affinity for binding extracellular domains of the human GnRH receptor that is comparable to murine GHR- 106.
- the antigen binding domain of the GHR-106 CAR has a specificity and affinity for binding extracellular domains of the human GnRH receptor that is comparable to humanized GHR-106.
- the antigen binding domain of the GHR-106 CAR has a binding affinity for the human GnRH receptor associated with a dissociation constant (KD) of at least 10 "7 M, 10 "8 M10 “9 M or 10 "10 M, or any value within that range.
- KD dissociation constant
- a hinge region 118 is provided that extends between the antigen binding domain of the GHR-106 CAR (110, 112, 114) and the transmembrane domain 120. Hinge region 118 ensures that the antigen binding domain (i.e. the scFv of GHR-106 in the illustrated embodiment) is free to bind to the GHR-106 CAR (110, 112, 114) and the transmembrane domain 120. Hinge region 118 ensures that the antigen binding domain (i.e. the scFv of GHR-106 in the illustrated embodiment) is free to bind to the
- hinge region 118 comprises the hinge domain of a CD8 molecule.
- any suitable hinge region that allows the antigen binding domain (e.g. the scFv of GHR- 106) of the GHR-106 CAR to bind to the extracellular domains of the GnRH receptor could be used.
- the transmembrane domain from a CD8 molecule is used to provide transmembrane domain 120.
- any suitable transmembrane domain that allows the antigen binding domain and the intracytoplasmic domain of the GHR-106 CAR to be coupled together and extend through the cell membrane of an immune cell could be used.
- the GHR-106 CAR comprises a 4-1 BB
- costimulatory domain 122 present on the intracellular portion of the protein. Without being bound by theory, it is believed that the 4-1 BB costimulatory domain costimulates T cells to improve CAR-T persistence in vivo. In some embodiments, the 4-1 BB
- the CD3 zeta subunit domain 124 performs the function of signaling within T-cells. Without being bound by theory, once the GnRH receptor is bound by the antigen binding domain of the GHR-106 CAR, the CD3 zeta subunit domain transmits an activation signal to the T-cell, to initiate killing of the cell expressing the GnRH receptor.
- Some embodiments of the invention provide a nucleotide vector for the introduction and expression of humanized GHR-106 monoclonal antibody or a fragment thereof in immune cells, such as T cells, to confer binding specificity for the extracellular domains of the human GnRH receptor on that immune cell.
- the nucleotide vector comprises a nucleic acid molecule encoding a GHR-106 CAR construct.
- the vector is a vector suitable for transduction into a target cell, such as a T cell.
- the vector is a vector suitable to be introduced into a target cell, such as an immune cell and including a T cell, by any available means of genetic engineering.
- the nucleotide vector comprises a lentiviral vector encoding a GHR-106 CAR construct as shown in FIG. 3.
- the exemplary nucleotide vector construct encodes a polypeptide having the amino acid sequence of SEQ ID NO:7.
- the polypeptide having the amino acid sequence of SEQ ID NO:7 is a fusion protein comprising a GHR-106 CAR and a cytokine 126, separated by a self-cleavable peptide 128 so that the two proteins can be separated after translation.
- the nucleotide vector provides for expression of a GHR- 106 CAR in a T cell after that T cell has been transduced with a suitable nucleotide vector construct that is capable of expressing a GHR-106 CAR.
- a nucleotide vector capable of expressing a GHR-106 CAR in a suitable host cell is provided.
- the nucleotide vector is provided as a lentiviral vector.
- FIG. 2A shows schematically a portion of the nucleotide sequence of an exemplary GHR-106 CAR lentiviral vector, which is an example of a nucleotide vector capable of expressing a GHR-106 CAR.
- FIG. 3 shows schematically the full structure of a nucleotide vector capable of expressing a GHR-106 CAR in a suitable host cell, in which the nucleotide vector comprises a transfer plasmid for use in a lentiviral gene therapy system.
- the nucleotide vector capable of expressing a GHR-106 CAR comprises nucleic acid sequences encoding the signal peptide 110, V H fragment 112, linker 114, V L fragment 116, hinge region 118, transmembrane domain 120, costimulatory domain 122, and CD3 zeta subunit domain 124 described above.
- the nucleotide vector capable of expressing a GHR-106 CAR further encodes a cytokine 126, which without being bound by theory may be important for T cell development.
- the nucleotide vector encodes the cytokine 126 so that it will be expressed as a C-terminal fusion protein with the GHR-106 CAR.
- the nucleotide vector capable of expressing a GHR-106 CAR further encodes a self-cleavage peptide 128 that interposes the GHR-106 CAR and the cytokine 126, so that after translation thereof, the GHR-106 CAR will self-cleave from the cytokine 126.
- a self-cleavage peptide sequence allows the expression of two proteins from the same RNA. After translation, the peptide containing the two proteins will self-cleave at the self-cleavable peptide sequence region.
- the cytokine 126 is IL-7, or another interleukin such as IL- 15.
- IL-7 interleukin
- any desired cytokine could be used, or additional cytokines separated by additional self-cleavage peptides could be used.
- the self-cleavage peptide 128 comprises 2A.
- any suitable self-cleaving peptide sequence could be used.
- the nucleotide vector capable of expressing a GHR-106 CAR comprises a promoter sequence 130, to drive expression of the GHR-106 CAR in vivo.
- the promoter is the EF-1 alpha promoter. In alternative embodiments, any suitable promoter can be used.
- nucleotide vector capable of expressing a GHR-106 CAR comprises a lentiviral plasmid 132.
- Lentiviral plasmid 132 is a transfer plasmid that can be used to transfect eukaryotic cells to produce viruses bearing the nucleotide sequences encoding the GHR-106 CAR, which can in turn be used to carry out genetic engineering of suitable immune cells of a subject, for example T cells, to produce immune cells that express the GHR-106 CAR.
- a post-transcriptional regulatory element is provided on the nucleotide vector.
- the post-transcriptional regulatory element is Woodchuck hepatitis virus post-transcriptional regulatory element 134, which stimulates the expression of transgenes via increased nuclear export.
- any suitable post-transcriptional regulatory element can be used.
- a 3' LTR 136 is provided on the nucleotide vector capable of expressing a GHR-106 CAR, to terminate transcription by the addition of a poly-A tract 137 just after the R sequence.
- a 5' LTR 138 is provided on the nucleotide vector capable of expressing a GHR-106 CAR, to act as a promoter for RNA polymerase II.
- the nucleotide vector capable of expressing a GHR-106 CAR contains a transcription promoter.
- the transcription promoter is a constitutive promoter.
- the transcription promoter is a Rous Sarcoma Virus (RSV) constitutive promoter 140.
- RSV Rous Sarcoma Virus
- the nucleotide vector capable of expressing a GHR-106 CAR contains a Gag sequence 142.
- Gag is a precursor structural protein of the lentiviral particle containing the matrix, capsid and nucleocapsid components.
- the nucleotide vector capable of expressing a GHR-106 CAR contains a Rev Response Element (RRE) 144, which is a sequence to which the Rev protein binds.
- RRE Rev Response Element
- the nucleotide vector capable of expressing a GHR-106 CAR contains a gene encoding VSV-G envelope protein (indicated as "env” 146).
- the nucleotide vector capable of expressing a GHR-106 CAR contains a central polypurine tract (cppt, 148), which is a recognition site for proviral DNA synthesis that increases transduction efficiency and transgene expression.
- cppt, 148 central polypurine tract
- the nucleotide vector capable of expressing a GHR-106 CAR contains an origin of replication (ori, 150) to allow for replication of the plasmid.
- the nucleotide vector capable of expressing a GHR-106 CAR contains an antibiotic resistance marker, which in the illustrated embodiment is an ampicillin resistance marker, Amp 152.
- an immune cell expressing a GHR-106 CAR is provided.
- a GHR-106 CAR is expressed on the surface of a suitable immune cell, e.g. a T cell or a natural killer, NK, cell.
- a GHR-106 CAR is present on the surface of a T cell or an NK cell and the GHR-106 CAR binds to the human GnRH receptor expressed on the surface of cancer cells.
- the GHR-106 CAR binds to human GnRH receptor expressed on the surface of cells with a specificity and an affinity comparable to that of humanized GHR-106 antibody.
- the GHR-106 CAR binds to human GnRH receptor on cancer cells, thereby mediating killing of the cancer cells by the T cell or NK cell.
- lentivirus bearing the nucleotide vector capable of expressing a GHR-106 CAR are used to carry out gene therapy.
- Suitable immune cells for example T cells, are harvested from either a cancer patient (for autologous CAR-T therapy) or from a healthy subject (for allogenic CAR-T therapy).
- the T cells are transduced with the nucleotide vector capable of expressing the GHR-106 CAR via a lentiviral vector.
- the genetically engineered T cells capable of expressing the GHR-106 CAR are then introduced into the body of the cancer patient to selectively kill cancer cells expressing the human GnRH receptor.
- the nucleotide vector capable of expressing a GHR-106 CAR is a lentiviral vector
- the lentiviral vector is introduced into the T cells as RNA via a lentivirus vector. Once inside the T cells, the RNA is reverse-transcribed to yield DNA, which integrates with the genome of the T cell via the viral integrase enzyme.
- Some embodiments of the present invention are directed to a genetically modified T cell capable of expressing a GHR-106 CAR.
- the genetically modified T cell is obtained via transduction with a nucleotide vector capable of expressing a GHR-106 CAR.
- the genetically modified T cell is produced by any suitable genetic modification technique, e.g. gene editing using clustered regularly interspaced short palindromic repeats ("CRISPR")/Cas9 technology can be carried out, so that the genetically modified T cell will produce a GHR-106 CAR.
- CRISPR clustered regularly interspaced short palindromic repeats
- the immune cell will cause the immune cell to express GHR-106 CAR incorporating an antigen- binding fragment of GHR-106 that binds to the extracellular domains of human GnRH receptor.
- the immune cells are T cells or natural killer (NK) cells.
- a method of treating cancer comprises: i) genetically modifying T cells obtained from a subject with suitable nucleotide vectors encoding a GHR-106 CAR construct; and ii) introducing the genetically modified T cells into the patient suffering from cancer.
- the T cells are obtained from the patient suffering from cancer.
- the T cells are obtained from a healthy subject, genetically modified, and then introduced into a patient suffering form cancer.
- the genetically modified immune cells Upon transduction or genetic engineering to introduce a nucleotide vector capable of expressing a GHR-106 CAR into immune cells such as T cells or NK cells, the genetically modified immune cells will then express the scFv chain of humanized GHR-106 antibody on their surface, which acts as an antigen binding domain.
- This immunoglobulin chain will bind to the human GnRH receptor expressed on the surface of cancer cells, and will result in cytotoxic killing of cancer cells via the T cells. Therefore, the GHR-106 CAR-T system can be utilized for therapeutic applications for treatment of some human cancers.
- a plurality of immune cells e.g. T cells or NK cells, that express a GHR-106 CAR construct can be isolated and stored in a frozen state, e.g. at - 80°C. Such cells can then be thawed at a future date for introduction into a patient who has a subsequent relapse of cancer during his or her lifetime.
- the GHR-106 CAR construct has broad potential therapeutic applications in all human cancers associated with a high level of expression of the human GnRH receptor.
- the type I GnRH receptor has been found to be overexpressed in cell lines derived from glioblastoma, lymphoma, leukemia, melanoma and neuroblastoma, and some embodiments of the invention may also be used for the treatment of these cancers.
- US patent No. 8163283 to Lee tested more than 30 different human cancer cell lines and found that all tested cells, except Jurkat cells (T-cell leukemia), showed expression of GnRH receptor.
- the cancer is glioblastoma, lymphoma, leukemia, melanoma, neuroblastoma, or cancer of the colon, liver, kidney, lung, breast, ovary, cervix, endometrial tissue, placenta, prostate, or pancreas.
- the cancer is a hormone-sensitive cancer.
- GnRH receptor on the surface of the cancer cell.
- lentiviral vector system has been described for use in the transduction of immune cells to express a GHR-106 CAR
- any suitable retroviral vector system could be used to carry out such transduction. Examples
- the full length of GHR-106 CAR nucleotide cassette construct is synthesized according to the established frame and scheme, and then sub-cloned into a lenti-Puro vector transfer plasmid using standard molecular biology techniques. The insert was confirmed by Sanger sequencing.
- the resulting construct is validated by endonuclease digestion, as shown in FIG. 4.
- the recombinant vector was digested with EcoRI-Xbal, yielding the expected 2079 bp fragment.
- HEK293T cells human embryonic kidney cells 293 are transfected to produce lentiviruses suitable for use in the genetic engineering of T cells to produce GHR-106 CAR.
- HEK293T cells are cultured overnight in complete culture medium, and are transfected with the GHR-106 transfer plasmid (plasmid 132), along with packaging plasmids including pGP (encoding Gag and Pol) and pVSVG envelope plasmid
- the DNA is mixed with polyethylenimine (PEI) and then cultured with the cells. After 48 hours, supernatant is harvested and filtered to produce the virus stock, which can be aliquoted and stored at - 80°C.
- PEI polyethylenimine
- Lentiviral copy number is determined (see e.g. Barczak et al., Mol. Biotechnol. , 2015, 57:195-200, which is hereby incorporated by reference herein).
- HT1080 cells a fibrosarcoma cell line
- Polybrene hexadimethrine bromide
- Virus and cells are incubated for 96 hours, then cells are washed with PBS. Genomic DNA is extracted using a Genomic DNA Purification Kit from Lifetech, and its concentration determined by NanoDrop 2000.
- a standard curve for WPRE woodchuck hepatitis virus post-transcriptional regulatory element
- ALB albumin
- LymphoprepTM density gradient medium is used to separate PBMC (peripheral blood mononuclear cells including T cells) from other components of whole blood samples.
- Magnetic DynabeadsTM CD3 are used to isolate CD3 + T cells, and resulting cells are washed with PBS and resuspended and cultured in X-vivo 15 medium.
- Lentiviral vector particles were used to transduce the T cells, with an MOI (multiplicity of infection) of 20. Lentiviral vector particles are defrosted and mixed with Polybrene (hexadimethrine bromide) and isolated T cells. After centrifugation, the cell pellet is harvested, resuspended in fresh medium, and cells are cultured.
- MOI multiplicity of infection
- RT qPCR was carried out to determine the number of copies of nucleotide vector encoding GHR-106 in lentivirus-transduced T cells.
- Genomic DNA is extracted from transduced T cells using a Genomic DNA Purification Kit (Lifetech). DNA concentration is determined using Nanodrop 2000.
- pUC-LTR and pUC-ALB plasmids are prepared, and serial dilutions are made to prepare the standard curve for RT qPCR.
- Primers used for ALB are those of SEQ ID NOS:1 1 , 12 and 13.
- Primers used for LTR are as follows below. PCR is carried out for 40 cycles.
- ALB and LTR standard curves are generated to determine copy number for GHR- 106 CAR validation in transduced T cells. After obtaining the Ct value, the Copy No. of GHR-106 CAR in the resultant recombinant T cells is calculated based on the formulation below.
- results for the standard curves for ALB and LTR are presented in FIGS. 6A and 6B, and results for the Ct value of the samples are given in Table 2.
- the average number of GHR-106 CAR gene copies in the genetically modified CAR-T cells was determined to be 2.2/cell. Table 2. Ct value of samples.
- C33A Tumor cells from a cell line of cervical carcinoma C33A (ATCC HTB-31 ) were employed as target tumor cells and cultured with GHR-106 CAR-T cells at three different E/T ratios under standard cell culture conditions.
- C33A cells are known to express GnRH: see e.g. US 8163283 to Lee.
- Target C33A cells are grown to logarithmic phase, then lifted with trypsin and incubated overnight in assay wells. Prior to the assay, the assay wells are aspirated completely to remove culture and the cells are washed with sterilized PBS. GHR-106 CAR-T cells obtained in Example 4.0 are resuspended in RPM I 1640 medium without FBS and added to each assay well. Following 6 hours of co-culturing of both C33A tumor cells and GHR-106 CAR-T cells, the supernatant was harvested for determination of amount of lactate dehydrogenase (LDH) reduced using LDH detection reagent and the OD value was recorded. The percentage of target cell lysis was calculated as follows below. Maxi Lysis and Mini lysis were determined using four wells containing target C33A cells without GHR-106 CAR T cells, and cell lysis buffer was added to the Maxi lysis wells.
- LDH lactate dehydrogenase
- the results of lysis assay strongly demonstrate that GHR-106 CAR-T cells are capable of killing the target tumor cells in a dose dependent manner.
- the untransduced T cells also showed a low degree of cytolytic effect compared to that of the transduced GHR-106 T cells. Without being bound by theory, this high background could potentially result from the activation of untransfected T cells by anti-CD3 and anti-CD28 antibodies in the assay system tested.
- the cell lytic effects of GHR-106 CAR-T cells on the tumor cells are clearly statistically significant (P 0.05- 0.001 ).
- the results of this example demonstrate that a GHR-106 CAR present on the surface of a genetically modified T cell can mediate cytotoxicity toward a target cell.
- the GHR-106 binds to the GnRH receptor present on a target cell expressing the GnHR receptor and mediates killing of the target cell by the genetically modified T cell.
- Example 7.0 Demonstration of Cytokine Release by CAR-T Cells Upon Co-Culturing with Tumor Cells using ELISA Assay
- cytokines including IL-2, IL-7 and IFN-gamma were quantitatively determined and repeated three times.
- FIGS. 8D, 8E, 8F, 9D, 9E, 9F and 10D, 10E, 10F The results suggest that significantly more cytokines were released when co-culturing C33A tumor cells with GHR-106 CAR-T cells than when co-culturing C33A tumor cells with untransfected T cells.
- GHR-106 CAR-T cells i.e. T cells transduced with a nucleotide vector capable of expressing a GHR-106 CAR
- GHR-106 CAR-T cells can effectively lead to cytotoxic killing of co-cultured tumor cells in vitro, and may eventually lead to significant anti-cancer efficacy in vitro or in vivo.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A chimeric antigen receptor (CAR) having an antigen binding domain capable of binding to extracellular domains of human GnRH receptor. The antigen binding domain can have a binding affinity and specificity similar to the GHR-106 antibody. Methods of making and using such CARs are provided. The CARs can be used to treat cancer.
Description
GHR-106 CHIMERIC ANTIGEN RECEPTOR CONSTRUCT AND
METHODS OF MAKING AND USING SAME
Reference to Related Applications
[0001] This application claims priority to, and the benefit of, United States provisional patent application No. 62/441380 filed 1 January 2017 and United States provisional patent application No. 62/480229 filed 31 March 2017. Both of the foregoing
applications are incorporated by reference herein for all purposes.
Technical Field
[0002] Some embodiments of the present invention relate to the fields of immunology, cell biology, molecular biology, and medicine, including cancer medicine. Some embodiments of the present invention relate to the field of a chimeric antigen receptor (CAR) that targets gonadotropin-releasing hormone (GnRH) receptor, nucleotide constructs encoding such a CAR, and methods of making and using same.
Background
[0003] Gonadotropin releasing hormone (GnRH) receptors are located on the external membrane of selected cell types. Through specific binding to the GnRH receptor, the anterior pituitary releases GnRH, a decapeptide hormone that stimulates the release of gonadotropin, luteinizing hormone (LH) and follicle stimulating hormone (FSH). Studies reveal that GnRH or its analogs can have anti-proliferative effects on cancer cells (Pati, D., et al., Endocrin (1995) 136:75-84; Choi, K.C., et al., J Clin Endocrinol & Metab (2001) 86:5075-5078, both of which are incorporated by reference herein for all purposes). GnRH analogs have been used to treat different cancers in humans and disorders in fertility regulation (Gnananpragasam, V.J., et al., J Pathol (2005) 206: 205-213; So, W. K., et al., FEBS Journal (2008) 275: 5496-551 1).
[0004] A shortcoming associated with GnRH and GnRH analogs is that they have a relatively short half-life in circulation. In contrast, monoclonal antibodies generally have a relatively long half-life in circulation.
[0005] The GHR-106 monoclonal antibody was generated in mice immunized against synthetic peptides corresponding to the extracellular domains of the human GnRH receptor. GHR-106 was found to behave as a GnRH analog. GHR-106 has a much longer half-life than other GnRH analogs known in the art. GnRH analogs have been
known for decades to treat different cancers in humans as well as disorders in fertility regulation.
[0006] US patent Nos. 8163283, 8361793, and 9273138, which are incorporated by reference herein in their entirety for all purposes, are of interest with respect to the subject matter described herein. The amino acid sequences for murine GHR-106 and humanized GHR-106 were disclosed in US patent No. 9273138 to Lee. Biochemical and immunological experiments demonstrate that both murine GHR-106 and humanized GHR-106 antibodies have high specificity and affinity to the extracellular domains of the human GnRH receptor, these domains being expressed on the surface of cancer cells of many tissue origins. For example, US patent No. 8163283 to Lee discloses that the extracellular domains of the human GnRH receptor are expressed on the surface of cancer cells originating from breast, cervix, colon, glioblastoma, hepatocellular, kidney, lung, lymphoma, leukemia, neuroblastoma, placenta, and prostate tissues.
[0007] Additionally, murine GHR-106 and humanized GHR-106 antibodies behave similarly to GnRH peptide analogs in that they can induce in vitro apoptosis in treated cancer cells. Furthermore, unlike GnRH peptide analogs, both the murine and
humanized forms of GHR-106 can induce complement-dependent cytotoxicity in treated cancer cells.
[0008] Chimeric antigen receptors (CARs) are artificial receptors that convey antigen specificity to cells, such as T cells. CAR in T cell therapy (CAR-T) technology combines T cell immunotherapy, gene therapy and immunotherapy. CAR-T has been used for cancer treatments and it involves modifying a patient's T cells. The modified T cells express CARs, which are antigen receptors recognizing cell surface antigens on tumor cells. Upon antigen binding, the modified T cells can initiate an immune response, such as the release of cytokine to induce tumor cell death. Attempts in using CAR-T to treat cancer have met with some success. Successful examples have been reported for CAR- T cell therapy of different types of blood cancers, for example by using a CD19-related CAR platform. US patent No. 8916381 , incorporated by reference herein in its entirety, discloses a method of treating leukemia with CAR-T. Brentjens et al. (Molecular Therapy: Treatment of Chronic Lymphocytic Leukemia with Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial. 18 Vol. Elsevier, 04/01/2010), incorporated by reference herein in its entirety, conducted a clinical trial to treat chronic lymphocytic leukemia with CAR-T. The modified T cells were designed to recognize CA19, which is expressed on most B-cell malignancies.
[0009] There remains a need for improved constructs and methods for selectively targeting and killing cancer cells.
[0010] The foregoing examples of the related art and limitations related thereto are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the drawings.
Summary
[0011] The following embodiments and aspects thereof are described and illustrated in conjunction with systems, tools and methods which are meant to be exemplary and illustrative, not limiting in scope. In various embodiments, one or more of the above- described problems have been reduced or eliminated, while other embodiments are directed to other improvements.
[0012] One aspect of the invention provides a nucleotide vector capable of expressing a GHR-106 CAR. In some aspects, the GHR-106 CAR encodes a polypeptide having from N-terminal to C- terminal an antigen binding domain capable of binding to an extracellular domain of human GnRH receptor, a hinge domain, a transmembrane domain; and an intracellular T cell signaling domain. In some aspects, the antigen binding domain is an scFv of GHR-106.
[0013] One aspect of the invention provides a polypeptide that is a GHR-106 CAR that has an antigen binding domain capable of binding to the extracellular domains of human GnRH receptor. In some aspects, the polypeptide that is a GHR-106 CAR has an antigen binding domain capable of binding to an extracellular domain of human GnRH receptor, a transmembrane domain, and an intracellular T cell signaling domain. In some aspects, immune cells that express the GHR-106 CAR are able to selective bind to and kill cells expressing the human GnRH receptor. In some embodiments, the cells expressing the human GnRH receptor are cancer cells.
[0014] One aspect of the invention provides a method of producing an immune cell capable of expressing a GHR-106 CAR. The method involves isolating the immune cells from the subject and genetically engineering the immune cells to express a GHR-106 CAR. In some aspects, the genetic engineering can be carried out using a lentiviral vector. In some aspects, the immune cells are introduced into the body of a patient
suffering from cancer or another disorder involving a high surface expression of human GnRH receptor to treat the cancer or the disorder.
[0015] In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the drawings and by study of the following detailed descriptions.
Brief Description of the Drawings
[0016] In drawings which illustrate non-limiting embodiments of the invention:
[0017] FIGS. 1A andl B show amino acid and nucleotide sequences, respectively, of the heavy chain of a humanized GHR-106 antibody (SEQ ID NOS:1-2). FIGS. 1 C-1 D show the amino acid and nucleotide sequences, respectively, of the light chain of a humanized GHR-106 antibody (SEQ ID NOS:3-4). The sequences of the humanized GHR-106 antibody were deduced from antibodies produced by a stable cell line, UY464-GHR106.
[0018] FIG. 2A is a schematic diagram showing the domains of a first example embodiment of a nucleotide vector capable of expressing a GHR-106 CAR. The illustrated embodiment is a CAR lentiviral vector.
[0019] FIGS. 2B and 2C show amino acid sequences of the scFv fragment of the exemplary GHR-106 CAR nucleotide vector construct shown in FIG. 2A. FIG. 2B shows the amino acid sequence of the VH domain of the scFv fragment (SEQ ID NO:5). FIG. 2C shows the amino acid sequence of the VL domain of the scFv fragment (SEQ ID NO:6).
[0020] FIG. 2D shows the protein sequence of the exemplary GHR-106 CAR construct shown in FIG. 2A fused with an IL7 cytokine (SEQ ID NO:7). Although the sequences of FIG. 2D have been separated into different sections to illustrate the different domains of the GHR-106 CAR fusion protein construct, the sequences are one continuous polypeptide.
[0021] FIG. 3 is a schematic diagram showing schematically an example embodiment of a complete recombinant GHR-106 CAR-T lentiviral vector construct. The amino acid sequence encoded by the GHR-106 CAR-T nucleotide vector construct comprises SEQ ID NO:7. In this example embodiment, the gene sequence of the GHR-106 CAR nucleotide vector construct is present in the form of a plasmid that can be used as a transfer plasmid to produce lentivirus capable of introducing the nucleotide vector capable of expressing the GHR-106 CAR into an immune cell, e.g. a T cell.
[0022] FIG. 4 shows the molecular weights of DNA fragments produced by digesting the exemplary GHR-106 CAR nucleotide vector construct shown in FIG. 3 with restriction endonucleases EcoRI and Xba\.
[0023] FIGS. 5A and 5B show qPCR standard curves used to reveal titers by lentivirus titration. FIG. 5A shows the WPRE standard curve and FIG. 5B shows the ALB standard curve.
[0024] FIGS. 6A and 6B show validation of the insertion of the GHR-106 CAR nucleotide vector into transduced T cells by using a standard curve of Ct (cycle threshold) value to determine copy number. FIG. 6A shows the ALB standard curve and FIG. 6B shows the LTR standard curve. These two standard curves were used to determine the average number of copies of the exemplary GHR-106 CAR-T nucleotide vector construct in genetically modified T cells.
[0025] FIGS. 7A, 7B and 7C show the results of three repeats of a lysis assay, where genetically modified T cells comprising copies of the exemplary GHR-106 CAR nucleotide vector construct were co-cultured with tumor cells. Data for three repeats of CAR-T validation demonstrated by lysis of target tumor cells by GHR-106 CAR-T cells as measured by lactate dehydrogenase (LDH) assay are shown.
[0026] FIGS. 8A, 8B, 8C, 9A, 9B, 9C and 10A, 10B, 10C show standard curves for three separate repeats of the same experiment for IL-2, IFN-gamma and IL-7, respectively. FIGS. 8D, 8E, 8F, 9D, 9E, 9F and 10D, 10E, 10F show the level of cytokines (D = IL-2, E= IFN-gamma and F = IL-7, respectively) produced by genetically modified T cells comprising copies of the exemplary GHR-106 CAR-T nucleotide vector construct, when the genetically modified T cells were co-cultured with cervical tumor (C33A) cells. Description
[0027] Throughout the following description specific details are set forth in order to provide a more thorough understanding to persons skilled in the art. However, well known elements may not have been shown or described in detail to avoid unnecessarily obscuring the disclosure. Accordingly, the description and drawings are to be regarded in an illustrative, rather than a restrictive, sense.
[0028] As used herein, the term "nucleic acid molecule" refers to a polymeric form of nucleotides of any length. The nucleotides can include either ribonucleotides (RNA) or deoxyribonucleotides (DNA).
[0029] The terms "antibody" and "immunoglobulins" refer to antibodies of any isotype and fragments of antibodies that bind specifically to an antigen. Some examples of
antibodies include but are not limited to humanized antibodies, chimeric antibodies, and proteins comprising an antigen-binding portion of an antibody.
[0030] The term "antibody fragment" refers to a portion of an antibody. Some examples of antibody fragments include but are not limited to an antigen binding (Fab) fragment, an F(ab')2 fragment, an Fab' fragment, or a variable domain (Fv).
[0031] The term "single-chain variable fragment" (scFv fragment) refers to a single polypeptide chain, comprising the variable regions of the light (VL) and heavy (VH) chains of an antibody. The VL and VH regions are joined by a suitable linker.
[0032] The term "affinity" refers to the strength of the binding interaction between a single biomolecule and its ligand or binding partner. In some embodiments, the strength of the binding interaction is measured by the equilibrium constant for the reversible binding of two molecules, which can be expressed as a dissociation constant (Kd).
[0033] The terms "treat", "treating" and "treatment" refer to an approach for obtaining desired clinical results. Desired clinical results can include, but are not limited to, reduction or alleviation of at least one symptom of a disease. For example, treatment can be diminishment of at least one symptom of disease, diminishment of extent of disease, stabilization of disease state, prevention of spread of disease, delay or slowing of disease progression, palliation of disease, diminishment of disease reoccurrence, remission of disease, prolonging survival with disease, or complete eradication of disease.
[0034] The terms "cancer cell" and "tumor cell" refer to cells, the growth and division of which can be typically characterized as unregulated. Cancer cells can be of any origin, including benign and malignant cancers, metastatic and non-metastatic cancers, and primary and secondary cancers.
[0035] The term "chimeric antigen receptor (CAR)" refers to an engineered receptor. A typical CAR has an antigen binding domain that binds to a desired target antigen, a transmembrane domain, and an intracytoplasmic domain. The antigen binding domain of a CAR can be provided by the scFv of a monoclonal antibody. The transmembrane domain and the intracytoplasmic domain can be provided by the CD3-zeta
transmembrane and ectodomains. A typical CAR will also include a signal peptide at its amino-terminal end, to direct the nascent translated protein into the endoplasmic reticulum so that the antigen binding domain will be presented on the surface of the immune cell in which the CAR is expressed.
[0036] In some embodiments, a chimeric antigen receptor (CAR) comprising an antigen- binding fragment of a humanized GHR-106 monoclonal antibody is provided, and is
referred to herein as a GHR-106 CAR. A GHR-106 CAR is a CAR that is able to bind to extracellular domains of the human GnRH receptor.
[0037] In some embodiments, the GHR-106 CAR comprises the scFv fragment of a humanized GHR-106 antibody, and can be expressed following introduction of a nucleotide vector encoding the GHR-106 CAR into suitable immune cells, for example, T cells. In some embodiments, the antigen binding domain of the GHR-106 CAR binds to the extracellular domains of human GnRH receptor. In some embodiments, the GHR- 106 CAR exhibits similar binding affinity and specificity towards the human GnRH receptor as does a humanized GHR-106 antibody.
[0038] Some embodiments of the invention relate to the field of a lentiviral chimeric antigen receptor (CAR) nucleotide construct including portions of a humanized GHR-106 gene that provides a nucleotide vector capable of expressing a GHR-106 CAR in a transduced immune cell. Humanized GHR-106 is murine GHR-106 monoclonal antibody in humanized form which recognizes and binds specifically the extracellular domains of the human GnRH receptor. The human GnRH receptor is highly expressed on the surface of cancer cells of many tissue origins.
[0039] In some embodiments, upon transduction of a nucleotide vector encoding the GHR-106 CAR into suitable immune cells, for example, T cells or NK cells isolated from an individual patient, the GHR-106 CAR-transduced immune cells will then express a GHR-106 CAR construct with an antigen binding region comprising an scFv chain of a humanized GHR-106 antibody. This immunoglobulin chain will bind to surface- expressed GnRH receptor on cancer cells and result in cytotoxic killing of the cancer cells. The human GnRH receptor is expressed in particular on the surface of cancer cells in hormone-sensitive forms of cancer. Therefore, the GHR-106 CAR system can potentially be utilized for therapeutic applications for treatment of human hormone- sensitive cancers.
[0040] Applications of GHR-106-related CAR-T technology in cancer immunotherapy can be achieved by genetically modifying appropriate immune cells, e.g. T cells, by insertion of a nucleotide vector encoding GHR-106 CAR, so that those immune cells will subsequently express a GHR-106 CAR comprising an scFv of GHR-106 that can bind to the GnRH receptor expressed on the cancer cell surface to induce apoptosis and related cytotoxic killing of tumor cells, in vitro and in vivo.
[0041] A GHR-106 CAR construct can be transduced into isolated immune cells, e.g. T cells, of a given patient. These modified immune cells, e.g. T cells, from the given patient can be expanded by in vitro culture, and then transfused to the same given patient. In
some embodiments, the isolated immune cells, e.g. T cells, are obtained from a healthy subject, genetically modified to insert a nucleotide vector capable of expressing a GHR- 106 CAR therein, and then introduced into the bloodstream of a patient suffering from cancer. Cancer immunotherapy using a GHR-106 CAR can be used in the treatment of cancer, for example for inhibition and/or reduction of tumor growth.
[0042] In view of the widespread expression of the human GnRH receptor on the surface of a large number of different varieties of human cancer cells, it can be expected that the GHR-106 CAR construct will have broad therapeutic applications to many forms of human cancers which have an associated high level of expression of the human GnRH receptor.
[0043] With reference to the figures, a specific example embodiment of a GHR-106 CAR is now described. In some embodiments, the antigen binding domain of the GHR-106 CAR comprises a peptide that binds to the extracellular domains of the GnRH receptor in a manner similar to the GHR-106 antibody. US patent No. 9273138 to Lee discloses the nucleotide sequence of humanized GHR-106 antibody. In that reference, the sequence was verified by repeated sequencing and molecular biological analysis. The antibody-producing stable cell line for a humanized GHR-106 antibody was established and disclosed by that reference.
[0044] The amino acid and nucleotide sequences of an example embodiment of a humanized GHR-106 monoclonal antibody are shown in FIGS. 1A-1 D. The heavy chain of the humanized GHR-106 antibody is encoded by the nucleotide sequence shown in FIG. 1 B (SEQ ID NO:2). The light chain of the humanized GHR-106 antibody is encoded by the nucleotide sequence shown in FIG. 1 D (SEQ ID NO:4). FIGS. 1A and 1 C show the corresponding amino acid sequences of the heavy and light chains, respectively, of the humanized GHR-106 antibody (SEQ ID NOS: 1 and 3, respectively). FIG. 2B shows the amino acid sequence of the heavy chain (VH) of the scFv of the humanized GHR-106 antibody (SEQ ID NO:5), and FIG. 2C shows the amino acid sequence of the light chain (V|_) of the scFv of the humanized GHR-106 antibody (SEQ ID NO:6).
[0045] With reference to FIG. 2A, the partial structure of an example embodiment of a nucleotide vector encoding a GHR-106 CAR is illustrated. In the example embodiment, the GHR-106 CAR comprises from N-terminal to C-terminal a signal peptide 110, a VH fragment of a GHR-106 monoclonal antibody 112, a linker 114, a VL fragment of a GHR- 106 monoclonal antibody 116, a hinge region 118, a transmembrane domain 120, a costimulatory domain 122, and a CD3 zeta subunit domain 124.
[0046] The signal peptide 110 is used to direct the translated GHR-106 CAR into the endoplasmic reticulum, so that the antigen binding domain of the GHR-106 CAR will be expressed on the surface of an immune cell. In the illustrated embodiment, the signal peptide 110 comprises the interleukin 2 signaling sequence (IL2ss), which is used to direct the CAR for cell membrane expression in an immune cell. In alternative
embodiments, any signaling domain that directs the CAR to be appropriately expressed in a membrane of an immune cell could be used.
[0047] The antigen binding domain in the exemplary embodiment of FIG. 2A comprises the VH region 112, linker 114 and VL region 116 that together are an scFv of a GHR-106 monoclonal antibody. In the exemplary embodiment described and characterized herein, the antigen binding domain of the GHR-106 CAR comprises the scFv of a humanized GHR-106 antibody, having the VH and VL regions of the humanized GHR-106 antibody having SEQ ID NOS:5 and 6, respectively shown in FIGS. 2B and 2C, joined by a peptide linker.
[0048] In alternative embodiments, the sequences of the VH and VL regions of antigen binding fragment of the GHR-106 CAR (i.e. the scFv of GHR-106) could be the VH and V|_ regions, respectively, of any other humanized GHR-106 antibody.
[0049] In alternative embodiments, any suitable peptide linker sequence could be used to join the VH and VL regions of the scFV of the GHR-106 antibody in the GHR-106 CAR. Some parameters limiting the nature of a linker used in an scFV are that it be sufficiently soluble and that it allow the VH and VL regions of the antibody to bind to the target antigen.
[0050] In example embodiments, the linker used in the scFV of the GHR-106 antibody can be between about 10 and about 25 amino acids in length, including any value therebetween e.g. 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23 or 24 amino acids in length. In some embodiments, the linker used in the scFV of the GHR-106 antibody is rich in glycine. In some embodiments, the linker used in the scFV of the GHR-106 antibody includes a plurality of serine and/or threonine residues, to enhance the solubility of the linker.
[0051] While in the illustrated embodiment, the linker region of the scFv joins the C- terminus of the VH portion of the GHR-106 antibody with the N-terminus of the VL portion of the GHR-106 antibody, in alternative embodiments, the linker region of the scFv could join the C-terminus of the VL portion of the GHR-106 antibody with the N-terminus of the VH portion of the GHR-106 antibody.
[0052] The antigen binding domain of the GHR-106 CAR enables immune cells that have been genetically engineered with a nucleotide vector encoding the GHR-106 CAR to specifically bind to the extracellular domains of human GnRH receptor, which is expressed in cancer cells.
[0053] In some embodiments, the GHR-106 CAR binds to an epitope in the N-terminal amino acid positions 1-29 of the human GnRH receptor. In some embodiments, the antigen binding domain of the GHR-106 CAR has a specificity and affinity for binding extracellular domains of the human GnRH receptor that is comparable to murine GHR- 106. In some embodiments, the antigen binding domain of the GHR-106 CAR has a specificity and affinity for binding extracellular domains of the human GnRH receptor that is comparable to humanized GHR-106.
[0054] In some embodiments, the antigen binding domain of the GHR-106 CAR has a binding affinity for the human GnRH receptor associated with a dissociation constant (KD) of at least 10"7 M, 10"8 M10"9 M or 10"10 M, or any value within that range.
[0055] In the illustrated embodiment, a hinge region 118 is provided that extends between the antigen binding domain of the GHR-106 CAR (110, 112, 114) and the transmembrane domain 120. Hinge region 118 ensures that the antigen binding domain (i.e. the scFv of GHR-106 in the illustrated embodiment) is free to bind to the
extracellular domains of the GnRH receptor in vivo. In the illustrated embodiment, hinge region 118 comprises the hinge domain of a CD8 molecule. In alternative embodiments, any suitable hinge region that allows the antigen binding domain (e.g. the scFv of GHR- 106) of the GHR-106 CAR to bind to the extracellular domains of the GnRH receptor could be used.
[0056] In the illustrated embodiment, the transmembrane domain from a CD8 molecule is used to provide transmembrane domain 120. In alternative embodiments, any suitable transmembrane domain that allows the antigen binding domain and the intracytoplasmic domain of the GHR-106 CAR to be coupled together and extend through the cell membrane of an immune cell could be used.
[0057] In the illustrated embodiment, the GHR-106 CAR comprises a 4-1 BB
costimulatory domain 122 present on the intracellular portion of the protein. Without being bound by theory, it is believed that the 4-1 BB costimulatory domain costimulates T cells to improve CAR-T persistence in vivo. In some embodiments, the 4-1 BB
costimulatory domain could be omitted. In some embodiments, the 4-1 BB costimulatory domain could be replaced by a different domain that improves CAR-T persistence in vivo.
[0058] In the illustrated embodiment, the CD3 zeta subunit domain 124 performs the function of signaling within T-cells. Without being bound by theory, once the GnRH receptor is bound by the antigen binding domain of the GHR-106 CAR, the CD3 zeta subunit domain transmits an activation signal to the T-cell, to initiate killing of the cell expressing the GnRH receptor.
[0059] Some embodiments of the invention provide a nucleotide vector for the introduction and expression of humanized GHR-106 monoclonal antibody or a fragment thereof in immune cells, such as T cells, to confer binding specificity for the extracellular domains of the human GnRH receptor on that immune cell. The nucleotide vector comprises a nucleic acid molecule encoding a GHR-106 CAR construct. In some embodiments, the vector is a vector suitable for transduction into a target cell, such as a T cell. In some embodiments, the vector is a vector suitable to be introduced into a target cell, such as an immune cell and including a T cell, by any available means of genetic engineering.
[0060] In one example embodiment, the nucleotide vector comprises a lentiviral vector encoding a GHR-106 CAR construct as shown in FIG. 3. The exemplary nucleotide vector construct encodes a polypeptide having the amino acid sequence of SEQ ID NO:7. The polypeptide having the amino acid sequence of SEQ ID NO:7 is a fusion protein comprising a GHR-106 CAR and a cytokine 126, separated by a self-cleavable peptide 128 so that the two proteins can be separated after translation.
[0061] In some embodiments, the nucleotide vector provides for expression of a GHR- 106 CAR in a T cell after that T cell has been transduced with a suitable nucleotide vector construct that is capable of expressing a GHR-106 CAR.
[0062] In some embodiments, a nucleotide vector capable of expressing a GHR-106 CAR in a suitable host cell is provided. In some embodiments, the nucleotide vector is provided as a lentiviral vector. FIG. 2A shows schematically a portion of the nucleotide sequence of an exemplary GHR-106 CAR lentiviral vector, which is an example of a nucleotide vector capable of expressing a GHR-106 CAR. FIG. 3 shows schematically the full structure of a nucleotide vector capable of expressing a GHR-106 CAR in a suitable host cell, in which the nucleotide vector comprises a transfer plasmid for use in a lentiviral gene therapy system.
[0063] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR comprises nucleic acid sequences encoding the signal peptide 110, VH fragment 112, linker 114, VL fragment 116, hinge region 118, transmembrane domain 120, costimulatory domain 122, and CD3 zeta subunit domain 124 described above.
[0064] In some embodiments, with reference to FIG. 2A, the nucleotide vector capable of expressing a GHR-106 CAR further encodes a cytokine 126, which without being bound by theory may be important for T cell development. In some embodiments, the nucleotide vector encodes the cytokine 126 so that it will be expressed as a C-terminal fusion protein with the GHR-106 CAR. In some such embodiments, the nucleotide vector capable of expressing a GHR-106 CAR further encodes a self-cleavage peptide 128 that interposes the GHR-106 CAR and the cytokine 126, so that after translation thereof, the GHR-106 CAR will self-cleave from the cytokine 126. A self-cleavage peptide sequence allows the expression of two proteins from the same RNA. After translation, the peptide containing the two proteins will self-cleave at the self-cleavable peptide sequence region.
[0065] In some embodiments, the cytokine 126 is IL-7, or another interleukin such as IL- 15. In alternative embodiments, any desired cytokine could be used, or additional cytokines separated by additional self-cleavage peptides could be used.
[0066] In the illustrated embodiment, the self-cleavage peptide 128 comprises 2A. In alternative embodiments, any suitable self-cleaving peptide sequence could be used.
[0067] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR comprises a promoter sequence 130, to drive expression of the GHR-106 CAR in vivo. In the illustrated embodiment of FIG. 2A, the promoter is the EF-1 alpha promoter. In alternative embodiments, any suitable promoter can be used.
[0068] With reference to FIG. 3 in which like reference numerals refer to like elements of FIG. 2A, additional elements present on an example embodiment of a nucleotide vector capable of expressing a GHR-106 CAR are shown. In the illustrated example embodiment of FIG. 3, the nucleotide vector capable of expressing a GHR-106 CAR comprises a lentiviral plasmid 132. Lentiviral plasmid 132 is a transfer plasmid that can be used to transfect eukaryotic cells to produce viruses bearing the nucleotide sequences encoding the GHR-106 CAR, which can in turn be used to carry out genetic engineering of suitable immune cells of a subject, for example T cells, to produce immune cells that express the GHR-106 CAR.
[0069] In some embodiments, a post-transcriptional regulatory element is provided on the nucleotide vector. In the illustrated embodiment, the post-transcriptional regulatory element is Woodchuck hepatitis virus post-transcriptional regulatory element 134, which stimulates the expression of transgenes via increased nuclear export. In some embodiments, any suitable post-transcriptional regulatory element can be used.
[0070] In some embodiments, a 3' LTR 136 is provided on the nucleotide vector capable of expressing a GHR-106 CAR, to terminate transcription by the addition of a poly-A tract 137 just after the R sequence.
[0071] In some embodiments, a 5' LTR 138 is provided on the nucleotide vector capable of expressing a GHR-106 CAR, to act as a promoter for RNA polymerase II.
[0072] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains a transcription promoter. In the illustrated embodiment, the transcription promoter is a constitutive promoter. In the illustrated embodiment, the transcription promoter is a Rous Sarcoma Virus (RSV) constitutive promoter 140.
[0073] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains a Gag sequence 142. Gag is a precursor structural protein of the lentiviral particle containing the matrix, capsid and nucleocapsid components.
[0074] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains a Rev Response Element (RRE) 144, which is a sequence to which the Rev protein binds.
[0075] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains a gene encoding VSV-G envelope protein (indicated as "env" 146).
[0076] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains a central polypurine tract (cppt, 148), which is a recognition site for proviral DNA synthesis that increases transduction efficiency and transgene expression.
[0077] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains an origin of replication (ori, 150) to allow for replication of the plasmid.
[0078] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR contains an antibiotic resistance marker, which in the illustrated embodiment is an ampicillin resistance marker, Amp 152.
[0079] In some embodiments, an immune cell expressing a GHR-106 CAR is provided. In some embodiments, a GHR-106 CAR is expressed on the surface of a suitable immune cell, e.g. a T cell or a natural killer, NK, cell.
[0080] In some embodiments, a GHR-106 CAR is present on the surface of a T cell or an NK cell and the GHR-106 CAR binds to the human GnRH receptor expressed on the surface of cancer cells. In some embodiments, the GHR-106 CAR binds to human GnRH receptor expressed on the surface of cells with a specificity and an affinity comparable to that of humanized GHR-106 antibody. The GHR-106 CAR binds to human GnRH receptor on cancer cells, thereby mediating killing of the cancer cells by the T cell or NK cell.
[0081] In some embodiments, lentivirus bearing the nucleotide vector capable of expressing a GHR-106 CAR are used to carry out gene therapy. Suitable immune cells, for example T cells, are harvested from either a cancer patient (for autologous CAR-T therapy) or from a healthy subject (for allogenic CAR-T therapy). The T cells are transduced with the nucleotide vector capable of expressing the GHR-106 CAR via a lentiviral vector. The genetically engineered T cells capable of expressing the GHR-106 CAR are then introduced into the body of the cancer patient to selectively kill cancer cells expressing the human GnRH receptor.
[0082] In some embodiments, the nucleotide vector capable of expressing a GHR-106 CAR is a lentiviral vector, and the lentiviral vector is introduced into the T cells as RNA via a lentivirus vector. Once inside the T cells, the RNA is reverse-transcribed to yield DNA, which integrates with the genome of the T cell via the viral integrase enzyme.
[0083] Some embodiments of the present invention are directed to a genetically modified T cell capable of expressing a GHR-106 CAR. In some embodiments, the genetically modified T cell is obtained via transduction with a nucleotide vector capable of expressing a GHR-106 CAR. In some embodiments, the genetically modified T cell is produced by any suitable genetic modification technique, e.g. gene editing using clustered regularly interspaced short palindromic repeats ("CRISPR")/Cas9 technology can be carried out, so that the genetically modified T cell will produce a GHR-106 CAR. This will cause the immune cell to express GHR-106 CAR incorporating an antigen- binding fragment of GHR-106 that binds to the extracellular domains of human GnRH receptor. In some embodiments, the immune cells are T cells or natural killer (NK) cells.
[0084] Some embodiments relate to methods of treating cancer. In one example embodiment, a method of treating cancer comprises: i) genetically modifying T cells obtained from a subject with suitable nucleotide vectors encoding a GHR-106 CAR construct; and ii) introducing the genetically modified T cells into the patient suffering from cancer. In some embodiments, the T cells are obtained from the patient suffering from cancer. In some embodiments, the T cells are obtained from a healthy subject, genetically modified, and then introduced into a patient suffering form cancer.
[0085] Upon transduction or genetic engineering to introduce a nucleotide vector capable of expressing a GHR-106 CAR into immune cells such as T cells or NK cells, the genetically modified immune cells will then express the scFv chain of humanized GHR-106 antibody on their surface, which acts as an antigen binding domain. This immunoglobulin chain will bind to the human GnRH receptor expressed on the surface of
cancer cells, and will result in cytotoxic killing of cancer cells via the T cells. Therefore, the GHR-106 CAR-T system can be utilized for therapeutic applications for treatment of some human cancers.
[0086] In some embodiments, a plurality of immune cells, e.g. T cells or NK cells, that express a GHR-106 CAR construct can be isolated and stored in a frozen state, e.g. at - 80°C. Such cells can then be thawed at a future date for introduction into a patient who has a subsequent relapse of cancer during his or her lifetime.
[0087] In view of the widespread expression of the GnRH receptor on the surface of many human cancer cells, it can be soundly predicted that the GHR-106 CAR construct has broad potential therapeutic applications in all human cancers associated with a high level of expression of the human GnRH receptor. The type I GnRH receptor has been found to be overexpressed in cell lines derived from glioblastoma, lymphoma, leukemia, melanoma and neuroblastoma, and some embodiments of the invention may also be used for the treatment of these cancers. US patent No. 8163283 to Lee tested more than 30 different human cancer cell lines and found that all tested cells, except Jurkat cells (T-cell leukemia), showed expression of GnRH receptor. Specifically, Lee tested cancer cell lines from: kidney (FS293), lung (A549, Calu-6, H441 , MRC-5, WI-38), lymphoma (HEL1), leukemia (K-562), melanoma (MMAN, MMRU), neuroblastoma (SH-SY5Y), human ovarian (SK-OV-3, OC-3-VGH, OVCAR-3), placenta (JEG-3, Bewo), prostate (DU145, PC-3) and T-cell leukemia (Jurkat). Schally et al. (Biol. Reprod. 2005,
73(5):851-859), which is incorporated by reference herein, found that the human GnRH receptor was expressed in a significant proportion of breast, ovarian, endometrial, prostate, renal, and pancreatic cancers.
[0088] In some embodiments, the cancer is glioblastoma, lymphoma, leukemia, melanoma, neuroblastoma, or cancer of the colon, liver, kidney, lung, breast, ovary, cervix, endometrial tissue, placenta, prostate, or pancreas.
[0089] In some embodiments, the cancer is a hormone-sensitive cancer.
[0090] While the exemplary embodiments described herein have been described with reference to human GnRH receptor, similar embodiments with appropriate modifications could be used in other mammals that suffer from cancers involving expression of the
GnRH receptor on the surface of the cancer cell.
[0091] While in one exemplary embodiment described herein a lentiviral vector system has been described for use in the transduction of immune cells to express a GHR-106 CAR, in alternative embodiments, any suitable retroviral vector system could be used to carry out such transduction.
Examples
[0092] Specific embodiments of the invention are described with reference to the following examples, which are intended to be illustrative and not limiting in nature.
Example 1.0 - Preparation of Nucleotide Vector Capable of Expressing GHR-106 - Target Plasmid
[0093] Using the sequences of the VH and VL portions of the humanized GHR-106 monoclonal antibody, the full length of GHR-106 CAR nucleotide cassette construct is synthesized according to the established frame and scheme, and then sub-cloned into a lenti-Puro vector transfer plasmid using standard molecular biology techniques. The insert was confirmed by Sanger sequencing.
[0094] The resulting construct is validated by endonuclease digestion, as shown in FIG. 4. The recombinant vector was digested with EcoRI-Xbal, yielding the expected 2079 bp fragment.
Example 2.0 - Preparation of Lentivirus Containing GHR-106 Transfer Plasmid
[0095] HEK293T cells (human embryonic kidney cells 293) are transfected to produce lentiviruses suitable for use in the genetic engineering of T cells to produce GHR-106 CAR. HEK293T cells are cultured overnight in complete culture medium, and are transfected with the GHR-106 transfer plasmid (plasmid 132), along with packaging plasmids including pGP (encoding Gag and Pol) and pVSVG envelope plasmid
(encoding Env, VSV-G) to form lentiviral vector particles. The DNA is mixed with polyethylenimine (PEI) and then cultured with the cells. After 48 hours, supernatant is harvested and filtered to produce the virus stock, which can be aliquoted and stored at - 80°C.
Example 3.0 - Lentivirus Titration
[0096] Lentiviral copy number is determined (see e.g. Barczak et al., Mol. Biotechnol. , 2015, 57:195-200, which is hereby incorporated by reference herein). HT1080 cells (a fibrosarcoma cell line) are grown, and serial dilutions of concentrated lentivirus are added to the cells together with Polybrene (hexadimethrine bromide). Virus and cells are incubated for 96 hours, then cells are washed with PBS. Genomic DNA is extracted
using a Genomic DNA Purification Kit from Lifetech, and its concentration determined by NanoDrop 2000.
[0097] A standard curve for WPRE (woodchuck hepatitis virus post-transcriptional regulatory element), used as the lentiviral-specific gene, and ALB (albumin), used as a single copy reference gene, is prepared for real-time qPCR using pUC-WPRE and pUC- ALB. PCR is carried out for 40 cycles.
[0098] The primers used for PCR and detection were as follows:
[0099] The standard curves of Ct value (cycle threshold) versus copy number obtained for WPRE and ALB are presented in FIGS. 5A and 5B. Results for the Ct value of the virus are presented in Table 1.
Table 1. Ct value of the virus.
WPRE ALB
G HR-106 22.21 22.3 22.09 22.12
[0100] The virus titer calculation is done using the following formula:
(CopyW PRE /Copy ALB * 2) * Cell No.
Lentivirus Titer TU/mL =
Volume of virus
and was determined to be 4.36 x 108 TU/mL.
[0101] This example demonstrates that lentiviral vectors were prepared. The results of lentiviral titration indicated that a lentiviral vector bearing the GHR-106 CAR transfer plasmid was successfully constructed with a high titer.
Example 4.0 - Isolation and Preparation of Primary GHR-106 CAR T-Cells
[0102] Lymphoprep™ density gradient medium is used to separate PBMC (peripheral blood mononuclear cells including T cells) from other components of whole blood samples. Magnetic Dynabeads™ CD3 are used to isolate CD3+ T cells, and resulting cells are washed with PBS and resuspended and cultured in X-vivo 15 medium.
[0103] Lentiviral vector particles were used to transduce the T cells, with an MOI (multiplicity of infection) of 20. Lentiviral vector particles are defrosted and mixed with Polybrene (hexadimethrine bromide) and isolated T cells. After centrifugation, the cell pellet is harvested, resuspended in fresh medium, and cells are cultured.
Example 5.0 - Validation of Insertion of GHR-106 CAR in Transduced T Cells
[0104] RT qPCR was carried out to determine the number of copies of nucleotide vector encoding GHR-106 in lentivirus-transduced T cells. Genomic DNA is extracted from transduced T cells using a Genomic DNA Purification Kit (Lifetech). DNA concentration is determined using Nanodrop 2000.
[0105] pUC-LTR and pUC-ALB plasmids are prepared, and serial dilutions are made to prepare the standard curve for RT qPCR. Primers used for ALB are those of SEQ ID NOS:1 1 , 12 and 13. Primers used for LTR are as follows below. PCR is carried out for 40 cycles.
[0106] ALB and LTR standard curves are generated to determine copy number for GHR- 106 CAR validation in transduced T cells. After obtaining the Ct value, the Copy No. of GHR-106 CAR in the resultant recombinant T cells is calculated based on the formulation below.
Average Copy No./cell =— ^LTR # 2
CopyALB
Results for the standard curves for ALB and LTR are presented in FIGS. 6A and 6B, and results for the Ct value of the samples are given in Table 2. The average number of GHR-106 CAR gene copies in the genetically modified CAR-T cells was determined to be 2.2/cell.
Table 2. Ct value of samples.
Sample LTR ALB
GHR-106 CAR-T cells 26.49 25.92 24.94 24.73
[0107] These qPCR results showed that the genes of the constructed GHR-106 CAR nucleotide vector was successfully transduced into T cells.
Example 6.0 - Lysis of Target Tumor Cells with GHR-106 CAR-T Cells
[0108] Tumor cells from a cell line of cervical carcinoma C33A (ATCC HTB-31 ) were employed as target tumor cells and cultured with GHR-106 CAR-T cells at three different E/T ratios under standard cell culture conditions. C33A cells are known to express GnRH: see e.g. US 8163283 to Lee.
[0109] Target C33A cells are grown to logarithmic phase, then lifted with trypsin and incubated overnight in assay wells. Prior to the assay, the assay wells are aspirated completely to remove culture and the cells are washed with sterilized PBS. GHR-106 CAR-T cells obtained in Example 4.0 are resuspended in RPM I 1640 medium without FBS and added to each assay well. Following 6 hours of co-culturing of both C33A tumor cells and GHR-106 CAR-T cells, the supernatant was harvested for determination of amount of lactate dehydrogenase (LDH) reduced using LDH detection reagent and the OD value was recorded. The percentage of target cell lysis was calculated as follows below. Maxi Lysis and Mini lysis were determined using four wells containing target C33A cells without GHR-106 CAR T cells, and cell lysis buffer was added to the Maxi lysis wells.
(ODeach well— ODmini lysis)
Lysis% =
ODmaxi lysis
The experiments were repeated three times as shown in FIGS. 7A-7C for comparison.
[0110] The results of lysis assay strongly demonstrate that GHR-106 CAR-T cells are capable of killing the target tumor cells in a dose dependent manner. The untransduced T cells also showed a low degree of cytolytic effect compared to that of the transduced GHR-106 T cells. Without being bound by theory, this high background could potentially result from the activation of untransfected T cells by anti-CD3 and anti-CD28 antibodies in the assay system tested. The cell lytic effects of GHR-106 CAR-T cells on the tumor cells are clearly statistically significant (P 0.05- 0.001 ).
[0111] Without being bound by theory, the results of this example demonstrate that a GHR-106 CAR present on the surface of a genetically modified T cell can mediate cytotoxicity toward a target cell. The GHR-106 binds to the GnRH receptor present on a target cell expressing the GnHR receptor and mediates killing of the target cell by the genetically modified T cell.
Example 7.0: Demonstration of Cytokine Release by CAR-T Cells Upon Co-Culturing with Tumor Cells using ELISA Assay
[0112] Upon co-culturing of CAR-T cells with C33A cancer cells for 8 hours, the secretions of different cytokines were determined by typical enzyme immunoassay (EIA). These cytokines including IL-2, IL-7 and IFN-gamma were quantitatively determined and repeated three times.
[0113] Briefly, cells are adjusted to logarithmic phase. Adherent cells are lifted with trypsin, and cells are inoculated into assay wells and incubated overnight. GHR-106 CAR-T cells are harvested by centrifugation and resuspended in 1640 medium without FBS. Target tumor cells are washed with sterilized PBS and GHR-106 CAR T-cells are added to each well and incubated at 37°C for 6 hours. Assay plates are centrifuged and supernatant is harvested for detection of IL-2, IL-7 and IFN-gamma using an ELISA assay kit.
[0114] Standard curves for three different repeats of the experiment for IL-2, IFN-gamma and IL-7 are shown in FIGS. 8A, 8B, 8C, 9A, 9B, 9C and 10A, 10B, 10C, respectively.
[0115] The results of cytokine release enzyme immunoassays for three different repeats assaying IL-2, IFN-gamma and IL-7, respectively, are presented in FIGS. 8D, 8E, 8F, 9D, 9E, 9F and 10D, 10E, 10F for comparison. The cytokine release assay results suggest that significantly more cytokines were released when co-culturing C33A tumor cells with GHR-106 CAR-T cells than when co-culturing C33A tumor cells with untransfected T cells.
[0116] These examples lead to the conclusion that GHR-106 CAR-T cells (i.e. T cells transduced with a nucleotide vector capable of expressing a GHR-106 CAR) can effectively lead to cytotoxic killing of co-cultured tumor cells in vitro, and may eventually lead to significant anti-cancer efficacy in vitro or in vivo.
[0117] To summarize, the examples discussed above show the following: 1) The results of lentivirus titration showed that the inventor successfully prepared the GHR-106 CAR lentiviral vectors at a high titer. 2) The qPCR results demonstrate that the lentiviral GHR- 106 CAR vector was transduced into T cells. 3) The lysis assay results demonstrate that
GHR-106 CAR-T cells were able to kill target tumor cells in a "dose-dependent" manner, although untransduced T cells also showed a cytolytic effect, which without being bound by theory may result from the activation of untransduced T cells by anti-CD3 and anti- CD28 antibodies. 4) The cytokine release assay results demonstrate that GHR-106 CAR-T cells secreted more cytokines than untransduced T cells after co-incubation with target cells.
[0118] While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions and sub-combinations as are consistent with the broadest interpretation of the specification as a whole.
Claims
A nucleotide vector capable of expressing a GHR-106 CAR.
A nucleotide vector as defined in claim 1 , wherein the nucleotide vector encodes a polypeptide having from N-terminal to C-terminal:
an antigen binding domain capable of binding to an extracellular domain of
human GnRH receptor;
a hinge domain;
a transmembrane domain; and
an intracellular T cell signaling domain.
A nucleotide vector as defined in claim 2, further encoding:
a signal peptide upstream of the N-terminal portion of the antigen binding
domain.
A nucleotide vector as defined in any one of claims 2 or 3, wherein the antigen binding domain comprises an scFv of GHR-106.
A nucleotide vector as defined in any one of claims 2 to 4 wherein:
the antigen binding domain comprises VH and VL regions of a humanized GHR- 106 monoclonal antibody joined by a linker;
the signal peptide comprises the interleukin 2 signaling sequence;
the hinge domain comprises the hinge domain of a CD8 molecule;
the transmembrane domain comprises the transmembrane domain of a CD8 molecule; and/or
the intracellular T cell signaling domain comprises a CD3 zeta subunit domain.
A nucleotide vector as defined in any one of claims 2 to 5, further comprising: a costimulatory domain; and/or
a cytokine positioned at the C-terminus of the intracellular T cell signaling domain and a self-cleavable peptide sequence interposing the intracellular T-cell signaling domain and the cytokine.
A nucleotide vector as defined in claim 6, wherein:
the costimulatory domain comprises a 4-1 BB costimulatory domain;
the cytokine comprises interleukin-7; and/or
the self-cleavable peptide sequence comprises the peptide sequence of 2A.
8. A nucleotide vector as defined in any one of claims 2 to 7 further comprising: a promoter positioned to drive expression of the GHR-106 CAR;
a post-transcriptional regulatory element;
a 3' LTR;
a 5' LTR;
a transcription promoter;
a Gag sequence;
a Rev Response Element (RRE);
a gene encoding an envelope protein (Env);
a central polypurine tract;
an origin of replication; and/or
an antibiotic resistance marker.
9. A nucleotide vector as defined in claim 8, wherein:
the promoter comprises EF-1 alpha promoter;
the post-transcriptional regulatory element comprises Woodchuck hepatitis virus post-transcriptional regulatory element;
the transcription promoter comprises a constitutive promoter, optionally Rous
Sarcoma Virus (RSV) constitutive promoter; and/or
the gene encoding the envelope protein (Env) comprises a gene encoding VSV- G envelope protein.
10. A nucleotide vector as defined in any one of claims 5 to 9, wherein the VH region of the humanized GHR-106 monoclonal antibody has the amino acid sequence of SEQ ID NO:5, and/or wherein the VL region of the humanized GHR-106 monoclonal antibody has the amino acid sequence of SEQ ID NO:6. 1 1. A nucleotide vector as defined in any one of claims 2 to 10, wherein the antigen- binding domain of the expressed protein binds to the extracellular domains of human GnRH receptor and with an affinity substantially equivalent to a humanized GHR-106 monoclonal antibody.
12. A nucleotide vector as defined in any one of claims 1 to 1 1 , having the general structure shown in FIG. 3
13. A polynucleotide molecule that encodes an amino acid having the sequence of SEQ ID NO:7.
An isolated nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide having from N-terminal to C-terminal:
a signaling domain;
an antigen binding domain capable of binding to extracellular domains of the human GnRH receptor;
a transmembrane domain;
a CD3-zeta signaling domain; and
a cytokine domain separated from the CD3-zeta signaling domain by a self- cleavable peptide.
A nucleotide vector for use in the genetic engineering of immune cells to cause the cells to express a GHR-106 CAR, the vector comprising a nucleotide vector, polynucleotide molecule or isolated nucleic acid molecule as defined in any one of claims 1 to 14.
A nucleotide vector as defined in claim 15, wherein the nucleotide vector comprises a lentiviral plasmid suitable for use as a transfer plasmid in a lentiviral vector system to transduce immune cells with a nucleotide sequence capable of expressing GHR-106 CAR.
A GHR-106 CAR comprising from N-terminal to C-terminal:
an antigen binding domain capable of binding to an extracellular domain of
human GnRH receptor;
a transmembrane domain; and
an intracellular T cell signaling domain.
A GHR-106 CAR as defined in claim 17, further comprising
a signal peptide positioned on the N-terminal side of the antigen binding domain; a hinge domain; and
an intracellular costimulatory domain.
A GHR-106 CAR as defined in any one of claims 17 or 18, wherein:
the antigen binding domain comprises VH and VL regions of a humanized GHR- 106 monoclonal antibody joined by a linker;
the signal peptide comprises the interleukin 2 signaling sequence;
the hinge domain comprises the hinge domain of a CD8 molecule;
the transmembrane domain comprises the transmembrane domain of a CD8 molecule;
the intracellular T cell signaling domain comprises a CD3 zeta subunit domain; and/or
the intracellular costimulatory domain comprises a 4-1 BB costimulatory domain.
20. A polypeptide having the amino acid sequence of SEQ ID NO.7.
21. An immune cell capable of expressing a GHR-106 CAR or polypeptide as defined in any one of claims 17 to 20.
22. An immune cell comprising a nucleotide sequence encoding a GHR-106 CAR. 23. An immune cell comprising a nucleotide vector, polynucleotide molecule or
isolated nucleic acid molecule as defined in any one of claims 1 to 14.
24. A method of producing an immune cell capable of expressing a GHR-106 CAR, the method comprising:
isolating immune cells from a subject; and
genetically engineering the immune cells using a nucleotide vector capable of expressing a GHR-106 CAR.
25. A method as defined in claim 24, wherein the step of genetically engineering the immune cells comprises using a lentiviral vector or carrying out genetic engineering using CRISPR/Cas9 technology. 26. A method of using an immune cell as defined in any one of claims 21 to 23 or produced by the method of any one of claims 24 or 25 for the treatment of cancer in a patient comprising administering the immune cell to the patient.
27. A method as defined in any one of claims 21 to 26, wherein the immune cell comprises a T cell or a natural killer (NK) cell. 28. A method as defined in claim 26, wherein the cancer comprises cells having a high surface expression of the human GnRH receptor.
29. A method as defined in claim 26, wherein the cancer comprises a hormone
sensitive cancer.
30. A method of treating a disorder in a human subject involving a high surface expression of the human GnRH receptor, the method comprising administering to the human subject an immune cell as defined in any one of claims 21 to 23 or produced by the method of any one of claims 24 or 25.
31. The method as defined in any one of claims 26 to 30, wherein the treatment comprises in vitro or in vivo expression of a GHR-106 CAR on the surface of the immune cells.
32. The method as defined in claim 31 , wherein binding of the antigen binding
domain of the GHR-106 CAR expressed by the immune cells to the human GnRH receptor expressed on cancer cells causes selective killing of the cancer cells, optionally by inducing apoptosis or causing cytotoxic killing of the cancer cells.
33. The method as defined in any one of claims 26 to 32, wherein the cancer
comprises glioblastoma, lymphoma, leukemia, melanoma, neuroblastoma, or cancer of the colon, liver, kidney, lung, breast, ovary, cervix, endometrial tissue, placenta, prostate, or pancreas.
34. A method as defined in any one of claims 26 to 33 comprising isolating immune cells from a patient and transducing an isolated nucleic acid molecule, polynucleotide molecule, nucleotide vector or lentiviral vector as defined in any one of claims 1 to 14 into the immune cells.
35. A method as defined in claim 34, further comprising re-introducing the transduced immune cells into the patient.
36. A method as defined in any one of claims 34 or 35, further comprising isolating transduced immune cells and storing the cells in a frozen state, wherein optionally the frozen cells can be thawed in the future for cancer recurrence in the patient, and/or serve for emergency therapy to a different patient who has a spontaneous cancer incidence.
37. The immune cell as defined in any one of claims 21 to 23 or produced by the method of any one of claims 24 or 25 which comprises a mammalian cell, optionally a human cell.
38. The method as defined in any one of claims 26 to 36, wherein the patient comprises a mammal, optionally a human.
39. A method of treating a condition associated with an elevated expression of
GnRH, the method comprising:
modifying T cells to express a GHR-106 CAR, wherein the GHR-106 CAR
comprises
a signaling domain,
a transmembrane domain,
a CD3 zeta signaling domain, and
an antigen binding domain, wherein the antigen binding domain comprises a polypeptide that binds to the extracellular domains of human GnRH receptor; and
administering the modified T cells to a human.
A method as defined in claim 39, wherein the antigen binding domain comprises an scFv of GHR-106.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3048317A CA3048317A1 (en) | 2017-01-01 | 2017-12-22 | Ghr-106 chimeric antigen receptor construct and methods of making and using same |
US16/474,936 US20190322754A1 (en) | 2017-01-01 | 2017-12-22 | Ghr-106 chimeric antigen receptor construct and methods of making and using same |
US17/589,474 US20220242960A1 (en) | 2017-01-01 | 2022-01-31 | Ghr-106 chimeric antigen receptor construct and methods of making and using same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762441380P | 2017-01-01 | 2017-01-01 | |
US62/441,380 | 2017-01-01 | ||
US201762480229P | 2017-03-31 | 2017-03-31 | |
US62/480,229 | 2017-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/474,936 A-371-Of-International US20190322754A1 (en) | 2017-01-01 | 2017-12-22 | Ghr-106 chimeric antigen receptor construct and methods of making and using same |
US17/589,474 Continuation US20220242960A1 (en) | 2017-01-01 | 2022-01-31 | Ghr-106 chimeric antigen receptor construct and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018119519A1 true WO2018119519A1 (en) | 2018-07-05 |
Family
ID=62707497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2017/051601 WO2018119519A1 (en) | 2017-01-01 | 2017-12-22 | Ghr-106 chimeric antigen receptor construct and methods of making and using same |
Country Status (3)
Country | Link |
---|---|
US (2) | US20190322754A1 (en) |
CA (1) | CA3048317A1 (en) |
WO (1) | WO2018119519A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019153075A1 (en) * | 2018-02-06 | 2019-08-15 | Vancouver Biotech Ltd. | Use of ghr-106 monoclonal antibody as a gnrh antagonist |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119518A1 (en) | 2017-01-01 | 2018-07-05 | Lee Chi Yu Gregory | Rp215 chimeric antigen receptor construct and methods of making and using same |
WO2023056361A1 (en) * | 2021-09-29 | 2023-04-06 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102775500A (en) * | 2012-08-03 | 2012-11-14 | 郑骏年 | Chimeric antigen receptor iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof |
US9273138B2 (en) * | 2012-07-27 | 2016-03-01 | Vancouver Biotech Ltd. | Humanized forms of monoclonal antibodies to human GnRH receptor |
-
2017
- 2017-12-22 WO PCT/CA2017/051601 patent/WO2018119519A1/en active Application Filing
- 2017-12-22 US US16/474,936 patent/US20190322754A1/en not_active Abandoned
- 2017-12-22 CA CA3048317A patent/CA3048317A1/en active Pending
-
2022
- 2022-01-31 US US17/589,474 patent/US20220242960A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273138B2 (en) * | 2012-07-27 | 2016-03-01 | Vancouver Biotech Ltd. | Humanized forms of monoclonal antibodies to human GnRH receptor |
CN102775500A (en) * | 2012-08-03 | 2012-11-14 | 郑骏年 | Chimeric antigen receptor iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof |
Non-Patent Citations (3)
Title |
---|
LEE G. ET AL.: "CA 215 and GnRH receptor as targets for cancer therapy", CANCER IMMUNOL. IMMUNOTHER., vol. 61, 2012, pages 1805 - 1817, XP035115252, ISSN: 1432-0851 * |
SIMMONS A ET AL.: "Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro", VIROLOGY JOURNAL, vol. 3, no. 8, 2006, pages 1 - 10, XP021019386, ISSN: 1743-422X * |
TANG XY ET AL.: "Third-generation CD 28/4-IBB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomized, open label phase I trial protocol", BMJ, vol. 6, 2016, pages 1 - 7, ISSN: 2044-6055 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019153075A1 (en) * | 2018-02-06 | 2019-08-15 | Vancouver Biotech Ltd. | Use of ghr-106 monoclonal antibody as a gnrh antagonist |
US11021541B2 (en) | 2018-02-06 | 2021-06-01 | Vancouver Biotech Ltd. | Method of inhibiting the gonadotropin-releasing hormone (GnRH) receptor by administering a GHR-106 monoclonal antibody |
EP3749367A4 (en) * | 2018-02-06 | 2021-12-01 | Vancouver Biotech Ltd. | Use of ghr-106 monoclonal antibody as a gnrh antagonist |
Also Published As
Publication number | Publication date |
---|---|
US20190322754A1 (en) | 2019-10-24 |
US20220242960A1 (en) | 2022-08-04 |
CA3048317A1 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220242960A1 (en) | Ghr-106 chimeric antigen receptor construct and methods of making and using same | |
WO2019149250A1 (en) | Chimeric antigen receptor (car) binding to bcma, and uses thereof | |
CN110872577B (en) | Modified immune cells and uses thereof | |
EP2771355B1 (en) | A MODIFIED EFFECTOR CELL (OR CHIMERIC RECEPTOR) FOR TREATING DISIALOGANGLIOSIDE Gp2-EXPRESSING NEOPLASIA | |
US20210213119A1 (en) | Improved therapeutic t cell | |
WO2020038492A1 (en) | Therapeutic agent comprising nucleic acid and tcr modified immune cell and use thereof | |
CN110526983B (en) | Improved anti-CD 19 CAR-T cell | |
TW201934574A (en) | A chimeric antigen receptor (CAR) binding to BCMA and use thereof | |
CN108004259B (en) | Chimeric antigen receptor targeting B cell maturation antigen and uses thereof | |
JP2017515504A (en) | Nucleic acid encoding chimeric antigen receptor protein and T lymphocyte expressing chimeric antigen receptor protein | |
WO2018006881A1 (en) | Recombinant immune-checkpoint receptor and application thereof | |
CN104910278B (en) | A kind of slow virus with high-efficiency transfection ability and biological activity for being used to prepare CART cells | |
CN111423517B (en) | Tumor cell stem-restricted CAR and application thereof | |
WO2018137294A1 (en) | Transgenic lymphocyte co-expressing anti-msln chimeric antigen receptor and non-functional egfr and use thereof | |
CN103965362B (en) | A kind of chimeric chemokine receptor for making T cell tend to tumor locus | |
WO2021093251A1 (en) | Fgfr4- and dr5-targeted chimeric antigen receptor t cell, preparation method therefor, and application thereof | |
WO2021093250A1 (en) | Fgfr4-targeted single-chain antibody, chimeric antigen receptor, chimeric antigen receptor t cell, preparation method therefor and application thereof | |
WO2017120997A1 (en) | Transgenic lymphocyte co-expressing egfrviii chimeric antigen receptor and non-functional egfr and uses of the lymphocyte | |
CN110526970A (en) | Target single-chain antibody, the Chimeric antigen receptor T cell and its preparation method and application of CD133 | |
JP7378152B2 (en) | Chimeric antigen receptor binding to SSEA4 and its use | |
CN110526987A (en) | Target Chimeric antigen receptor, the Chimeric antigen receptor T cell and its preparation method and application of CD133 | |
US11447562B2 (en) | RP215 chimeric antigen receptor construct and methods of making and using same | |
CN108484778B (en) | Chimeric antigen receptor construct of humanized GHR106 monoclonal antibody, nucleic acid molecule and application | |
CN110699371A (en) | Fc gamma RIIa-based chimeric gene and application thereof | |
WO2021036245A1 (en) | Chimeric antigen receptor t cell carrying safety switch and targeting egfrvⅲ, and preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17886120 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3048317 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17886120 Country of ref document: EP Kind code of ref document: A1 |